Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Correction to CureVac 2nd Update Article on Sept. 14

09/15/2021 | 02:53am EDT

In late June, CureVac published final data showing that its vaccine had demonstrated efficacy of 48% against Covid-19. "CureVac Shares Fall Premarket on Termination of Vaccine Contracts With Wacker Chemie, Celonic -- 2nd Update," at 1314 GMT Sept. 14, cited interim data from mid-June which showed the vaccine demonstrating a 47% efficacy.

(END) Dow Jones Newswires

09-15-21 0453ET

Stocks mentioned in the article
ChangeLast1st jan.
CUREVAC N.V. 3.00% 39.53 Delayed Quote.-52.66%
NOVARTIS AG 0.66% 76.52 Delayed Quote.-9.12%
WACKER CHEMIE AG -1.41% 153.45 Delayed Quote.33.32%
All news about CUREVAC N.V.
10/22CUREVAC N : Deutsche Bank Starts CureVac at Hold with $35 Price Target
MT
10/18CUREVAC N : Shareholder dievini Files Shareholding Change with US Regulator; Stock Down 5%
MT
10/18PRESS RELEASE : dievini explains reasons for changes in shareholdings in CureVac due to le..
DJ
10/15CureVac Shares Down 12%
DJ
10/13CUREVAC N : EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by Cur..
AQ
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
MT
10/12Health Care Stocks Extending Retreat Ahead of Tuesday Close
MT
10/12Equities Choppy Midday as Clarida Says Fed Would Respond to Rise in Inflation Expectati..
MT
10/12MIDDAY REPORT : US Stocks Choppy as Clarida Says Fed Would Respond to Rise in Inflation Ex..
MT
10/12Health Care Stocks Falling Despite Moderate Rise Among Biotech Companies
MT
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 131 M 153 M 153 M
Net income 2021 -325 M -380 M -380 M
Net cash 2021 1 446 M 1 689 M 1 689 M
P/E ratio 2021 -16,8x
Yield 2021 -
Capitalization 6 472 M 7 507 M 7 560 M
EV / Sales 2021 38,4x
EV / Sales 2022 0,60x
Nbr of Employees 505
Free-Float 45,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 33,09 €
Average target price 56,47 €
Spread / Average Target 70,7%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-52.66%7 507
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.97%25 528